| Hepatic infarction following percutaneous ethanol injection therapy for hepatocellular carcinoma. | |
| | |
MedLine Citation:
|
PMID: 9872612 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We report on two patients who developed hepatic infarction after undergoing percutaneous ethanol injection therapy (PEIT) for hepatocellular carcinoma (HCC). In both cases, liver function parameters deteriorated immediately after the ethanol injection, and enhanced computed tomography images showed a wedge-shaped avascular low-density area due to hepatic infarction. In one patient, PEIT was performed for a nodule treated with transcatheter arterial infusion (TAI) using a suspension of styrene maleic acid neocarzinostatin (SMANCS) 4 weeks before. In the other patient, TAI with SMANCS had been carried out 14 months previously for a different nodule in the same segment where the nodule treated with PEIT was located. When PEIT is used for patients with HCC who have previously undergone TAI, especially with SMANCS, PEIT may induce hepatic infarction. |
| | |
Authors:
|
T Seki; M Wakabayashi; T Nakagawa; M Imamura; T Tamai; A Nishimura; N Yamashiki; A Okamura; K Inoue |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: European journal of gastroenterology & hepatology Volume: 10 ISSN: 0954-691X ISO Abbreviation: Eur J Gastroenterol Hepatol Publication Date: 1998 Nov |
Date Detail:
|
Created Date: 1999-02-25 Completed Date: 1999-02-25 Revised Date: 2009-10-16 |
Medline Journal Info:
|
Nlm Unique ID: 9000874 Medline TA: Eur J Gastroenterol Hepatol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 915-8 Citation Subset: IM |
Affiliation:
|
Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
administration & dosage,
therapeutic use Carcinoma, Hepatocellular / complications, drug therapy* Catheterization, Peripheral Ethanol / adverse effects, therapeutic use* Humans Infarction / etiology*, radiography Injections, Intralesional Liver / blood supply*, radiography Liver Cirrhosis / complications Liver Neoplasms / complications, drug therapy* Male Maleic Anhydrides / administration & dosage, therapeutic use Middle Aged Polystyrenes / administration & dosage, therapeutic use Tomography, X-Ray Computed Zinostatin / administration & dosage, analogs & derivatives, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Maleic Anhydrides; 0/Polystyrenes; 0/poly(maleic acid-styrene)neocarzinostatin; 64-17-5/Ethanol; 9014-02-2/Zinostatin |
| Comments/Corrections | |
Comment In:
|
Eur J Gastroenterol Hepatol. 1998 Nov;10(11):907-9
[PMID:
9872610
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The diagnosis of gluten sensitivity and coeliac disease--the two are not mutually inclusive.
Next Document: Diagnosis of gluten-sensitive enteropathy: is exclusive reliance on histology appropriate?